State Street
ABEO icon

State Street’s Abeona Therapeutics ABEO Stock Holding History

State Street’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.29M Buy
957,328
+58,890
+7% +$294K ﹤0.01% 3021
2025
Q4 		$4.73M Buy
898,438
+182,284
+25% +$918K ﹤0.01% 3021
2025
Q3 		$3.78M Buy
716,154
+130,274
+22% +$826K ﹤0.01% 3101
2025
Q2 		$3.33M Buy
585,880
+390,276
+200% +$2.22M ﹤0.01% 3112
2025
Q1 		$931K Buy
195,604
+12,000
+7% +$65.3K ﹤0.01% 3442
2024
Q4 		$1.02M Buy
183,604
+24,309
+15% +$150K ﹤0.01% 3485
2024
Q3 		$1.01M Sell
159,295
-2,600
-2% -$13.6K ﹤0.01% 3485
2024
Q2 		$686K Buy
161,895
+75,900
+88% +$387K ﹤0.01% 3529
2024
Q1 		$623K Buy
85,995
+9,000
+12% +$57K ﹤0.01% 3592
2023
Q4 		$386K Buy
76,995
+25,900
+51% +$114K ﹤0.01% 3703
2023
Q3 		$215K Hold
51,095
– – ﹤0.01% 3922
2023
Q2 		$206K Buy
51,095
+7,800
+18% +$27.3K ﹤0.01% 4001
2023
Q1 		$122K Sell
43,295
-9,200
-18% -$24K ﹤0.01% 4260
2022
Q4 		$162K Buy
52,495
+37,400
+248% +$140K ﹤0.01% 4192
2022
Q3 		$46K Sell
15,095
-1
-0% -$4 ﹤0.01% 4674
2022
Q2 		$78K Buy
15,096
+2,984
+25% +$15.1K ﹤0.01% 4612
2022
Q1 		$95K Hold
12,112
– – ﹤0.01% 4654
2021
Q4 		$102K Sell
12,112
-264
-2% -$4.85K ﹤0.01% 4574
2021
Q3 		$347K Hold
12,376
– – ﹤0.01% 4121
2021
Q2 		$483K Sell
12,376
-45,388
-79% -$1.85M ﹤0.01% 3869
2021
Q1 		$2.71M Buy
57,764
+8,159
+16% +$449K ﹤0.01% 3312
2020
Q4 		$1.95M Buy
49,605
+9,887
+25% +$337K ﹤0.01% 3389
2020
Q3 		$1.01M Buy
39,718
+968
+2% +$61K ﹤0.01% 3432
2020
Q2 		$2.82M Buy
38,750
+737
+2% +$50.9K ﹤0.01% 3044
2020
Q1 		$2M Buy
38,013
+13,550
+55% +$905K ﹤0.01% 3073
2019
Q4 		$2M Sell
24,463
-968
-4% -$68.3K ﹤0.01% 3246
2019
Q3 		$1.44M Buy
25,431
+912
+4% +$68.3K ﹤0.01% 3323
2019
Q2 		$2.93M Buy
24,519
+1,769
+8% +$297K ﹤0.01% 3079
2019
Q1 		$4.19M Buy
22,750
+667
+3% +$119K ﹤0.01% 2829
2018
Q4 		$3.94M Sell
22,083
-65,173
-75% -$14.2M ﹤0.01% 2833
2018
Q3 		$27.9M Sell
87,256
-35,119
-29% -$12.5M ﹤0.01% 1946
2018
Q2 		$48.9M Buy
122,375
+26,029
+27% +$11.4M ﹤0.01% 1506
2018
Q1 		$34.6M Buy
96,346
+6,075
+7% +$2.26M ﹤0.01% 1681
2017
Q4 		$35.8M Buy
90,271
+76,745
+567% +$31.7M ﹤0.01% 1664
2017
Q3 		$5.76M Buy
13,526
+1,648
+14% +$443K ﹤0.01% 2732
2017
Q2 		$1.9M Buy
+11,878
New +$1.62M ﹤0.01% 3151
2016
Q2 		– Sell
-2,555
Closed -$162K – 3725
2016
Q1 		$162K Sell
2,555
-62
-2% -$4.11K ﹤0.01% 3508
2015
Q4 		$219K Sell
2,617
-96
-4% -$9.63K ﹤0.01% 3469
2015
Q3 		$274K Buy
2,713
+214
+9% +$28.4K ﹤0.01% 3424
2015
Q2 		$316K Buy
+2,499
New +$375K ﹤0.01% 3432

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street's ABEO Position: Q1 2026 in Review

State Street increased its Abeona Therapeutics (ABEO) stake by 6.6% in Q1 2026, buying an estimated $294K and bringing the position to 957,328 shares worth $4.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

State Street first reported a position in ABEO in Q2 2015 and has held it in 40 quarters since. The position peaked at $48.9M in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • State Street held 957,328 shares of Abeona Therapeutics worth $4.29M as of Q1 2026.
  • State Street bought 58,890 Abeona Therapeutics shares in Q1 2026, an estimated $294K.
  • Abeona Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3021 holding.
  • State Street first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 40 quarters since.
  • State Street's Abeona Therapeutics position peaked at $48.9M in Q2 2018.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.